Open AccessTiming of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Author(s) -
Jeffrey S. A. Stringer,
Moses Sinkala,
Victoria Chapman,
Edward P. Acosta,
Grace M. Aldrovandi,
Victor Mudenda,
Julia P. Stout,
Robert L. Goldenberg,
Rosemary Kumwenda,
Sten H. Vermund
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200307250-00010
Subject(s) - nevirapine , medicine , transmission (telecommunications) , obstetrics , drug , pregnancy , human immunodeficiency virus (hiv) , pediatrics , virology , pharmacology , viral load , antiretroviral therapy , biology , electrical engineering , genetics , engineering
Single-dose intrapartum and neonatal nevirapine (NVP) reduces perinatal HIV transmission and is in increasingly common use throughout the developing world.